18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
about
Imaging tumour hypoxia with positron emission tomographyPositron emission tomography to assess hypoxia and perfusion in lung cancerIntegrating Imaging Data into Predictive Biomathematical and Biophysical Models of CancerMolecular mechanisms of hypoxia in cancer.PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidenceHypoxia in head and neck cancer in theory and practice: a PET-based imaging approachHypoxia as a biomarker for radioresistant cancer stem cells.Evaluation of hypoxia in a feline model of head and neck cancer using ⁶⁴Cu-ATSM positron emission tomography/computed tomography.F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapyImaging hypoxia to improve radiotherapy outcome.Modelling tumour oxygenation, reoxygenation and implications on treatment outcome.Role of (18)F-FDG PET-CT in head and neck squamous cell carcinomaMolecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer.Hypoxia in Head and Neck Tumors: Characteristics and Development during Therapy.Molecular imaging of tumor hypoxia with positron emission tomography.The role of necrosis, acute hypoxia and chronic hypoxia in (18)F-FMISO PET image contrast: a computational modelling study.Tumor hypoxia: a new PET imaging biomarker in clinical oncology.The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.A review of the predictive role of functional imaging in patients with mucosal primary head and neck cancer treated with radiation therapy.Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [18F]Fluoromisonidazole ([18F]FMISO) Kinetic Analysis and Invasive Oxygen Measurements.Hypoxia as a Biomarker and for Personalized Radiation Oncology.MiR-210 links hypoxia with cell proliferation regulation in human Laryngocarcinoma cancer.Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.Robustness of quantitative hypoxia PET image analysis for predicting local tumor control.Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine.
P2860
Q26851422-329FCAEE-E9AB-41AD-B595-93E218E51546Q27026940-E7F73AB9-40A1-4E93-BE7C-2AB7D5389782Q30659261-B2F65A67-AD57-4B57-BDE0-876517756BB6Q33705108-871A7299-71F4-4E0C-8CB6-D85A12CEBA79Q33818999-B8AABF9B-0264-498D-B189-EF4FB970CF4EQ34151551-90C5B990-B1E9-4F1E-AAC5-1A605F798BB5Q34420732-D25AB4CC-8F13-432C-9447-0726F9905ADCQ34696310-5B17A3E7-9479-4DD6-950F-34562F35E020Q35116993-4EE79581-C682-46D0-9D47-55EAAC4D2A33Q38059626-CECDBCDA-5BF8-42A4-A9F3-EFF521FD79ABQ38080844-4DEB6050-A7A6-415C-98D2-1C4AE5E12AFEQ38101933-C083C650-0691-48F4-BD17-C6F5FDF3274CQ38134094-C3D21B2F-AFA5-4ED0-84A2-3F49BCC88451Q38134761-EA74770C-4044-410C-943C-F9666B743E26Q38199721-32C4BFE4-AEE1-490A-986A-9437A4EF6F67Q38404220-4DF65A18-EE0D-492B-A507-F39939C1390BQ38411275-DC513469-A1E6-48D4-893C-5D7D1BD7A774Q38478344-75D951AB-FA82-472E-A686-52BD71413BCDQ38836743-48E373FD-C834-4FF0-AD39-9552A3BD7732Q38837272-5D3DE749-F9CC-4F73-A476-532B47DA45F3Q38869433-115E74CE-CFBE-458C-A0E4-F1ACBE1DB171Q38914407-B8669F4B-E46C-4BA5-8956-62ADADD6DE44Q51079367-01514668-75E4-4D37-860C-2010D2F73DC6Q52990174-D97C56F3-94A5-4202-8B74-DC8101D23C94Q53109990-73F30A16-DAF9-4CD3-BA38-B29D784AFBAF
P2860
18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
18F-fluoromisonidazole positro ...... neck squamous cell carcinoma.
@en
18F-fluoromisonidazole positro ...... neck squamous cell carcinoma.
@nl
type
label
18F-fluoromisonidazole positro ...... neck squamous cell carcinoma.
@en
18F-fluoromisonidazole positro ...... neck squamous cell carcinoma.
@nl
prefLabel
18F-fluoromisonidazole positro ...... neck squamous cell carcinoma.
@en
18F-fluoromisonidazole positro ...... neck squamous cell carcinoma.
@nl
P2093
P2860
P1476
18F-fluoromisonidazole positro ...... d neck squamous cell carcinoma
@en
P2093
Hiroshi Yamazaki
Keizo Fujiwara
Masahiro Kikuchi
Michio Senda
Shin-ya Hori
Yasushi Naito
Yosuke Tona
P2860
P2888
P304
P356
10.1007/S12149-011-0508-9
P577
2011-07-01T00:00:00Z